In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Amgen (NASDAQ:AMGN) in comparison to its major competitors within the Biotechnology industry. By analyzing crucial financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Amgen Background
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
Amgen Inc | 19.14 | 18.81 | 5.40 | 23.97% | $3.6 | $5.1 | 3.77% |
AbbVie Inc | 40.90 | 21.79 | 4.80 | 14.25% | $4.74 | $7.44 | -5.97% |
Gilead Sciences Inc | 16.92 | 4.41 | 3.64 | 10.03% | $3.23 | $5.49 | 0.11% |
Regeneron Pharmaceuticals Inc | 23.96 | 3.68 | 7.30 | 4.12% | $1.23 | $2.93 | 14.53% |
Vertex Pharmaceuticals Inc | 26.29 | 5.46 | 9.44 | 6.47% | $1.23 | $2.16 | 6.39% |
Biogen Inc | 23.79 | 2.39 | 3.48 | -0.47% | $0.05 | $1.87 | 0.87% |
BioNTech SE | 8.51 | 1.15 | 3.50 | 0.81% | $0.27 | $0.24 | -74.13% |
Genmab A/S | 34.23 | 4.68 | 8.64 | 7.11% | $2.71 | $4.64 | 16.08% |
Biomarin Pharmaceutical Inc | 120.70 | 3.58 | 7.69 | 0.83% | $0.07 | $0.46 | 15.04% |
Incyte Corp | 29.10 | 2.49 | 3.42 | 3.54% | $0.26 | $0.86 | 11.63% |
Neurocrine Biosciences Inc | 61.73 | 5.76 | 6.62 | 4.31% | $0.12 | $0.49 | 28.59% |
United Therapeutics Corp | 13.33 | 1.99 | 5.43 | 4.81% | $0.38 | $0.54 | 18.1% |
Grifols SA | 255.09 | 1.06 | 1 | 0.99% | $0.25 | $0.63 | 3.66% |
Average | 54.55 | 4.87 | 5.41 | 4.73% | $1.21 | $2.31 | 2.91% |